top of page

Depression Nasal Spray

1440 Daily Digest

The Food and Drug Administration approved pharma giant Johnson & Johnson's nasal spray Spravato yesterday, making it the first approved standalone drug therapy for treatment-resistant depression. 


Roughly a third of the 21 million American adults diagnosed with major depressive disorder (see overview and statistics) do not respond to at least two standard treatments for the condition. Participants in clinical trials of Spravato showed relief from symptoms—including persistent sadness, low energy, and suicidal ideation—as quickly as 24 hours after receiving the drug, weeks faster than typical oral antidepressants. The nasal spray—approved in 2019 for use in tandem with oral drugs—saw over $750M in sales last year, and Johnson & Johnson expects that number to approach $5B annually. 


Because the drug—whose generic name is esketamine—is derived from ketamine, a hallucinogen used for anesthetic purposes, its use is restricted to clinics where the patient is monitored for two hours. More than 3,000 treatment centers in the US are currently certified to dispense it.

Opmerkingen


  • White Facebook Icon

© 2024 389 Country. Powered by Talt Multi Media

bottom of page